1naresh
Array ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) ) 1nareshArray ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) )Table 1:Clinical characteristics and outcomes associated with IWMDR in children with cerebral malariaa
IWMDR+ IWMDR− OR 95% CI P Value Clinical characteristics Admission temperature (°C) 38.9 ± 1.1 38.8 ± 1.2 1.11 0.87–1.42 .40 Plasma lactic acid levels (mmol/L) 5.4 ± 3.6 6.9 ± 4.5 0.91 0.85–0.98 .02 Systolic blood pressure (mm Hg) 41.2 ± 214.7 74.9 ± 137.6 1.00 0.99–1.00 .14 HIV status 5 (9.6%) 32 (16.3%) 0.55 0.20–1.48 .23 Reported preadmission seizure 53 (89.8%) 171 (83.0%) 1.80 0.72–4.52 .21 Plasma glucose level (mmol/L) 6.4 ± 2.1 6.7 ± 3.6 0.97 0.89–1.06 .49 Plasma HRP-II levels 10.2 ± 10.2 10.8 ± 10.1 0.99 0.96–1.02 .67 Received anticonvulsant at admission 35 (57.4%) 148 (71.2%) 0.55 0.30–0.98 .04 Admission Blantyre coma scale score 1.4 ± 0.6 1.3 ± 0.6 1.44 0.90–2.31 .13 Admission white blood cell count × 10−9/L 10.5 ± 7.9 11.3 ± 7.9 0.98 0.95–1.03 .51 Platelet count × 10−9/L 56 ± 60 59 ± 64 1.00 1.00–1.00 .81 EEG characteristics Average voltage (μV) 128.9 ± 50.7 104.5 ± 53.5 1.01 1.00–1.02 .02 Maximum voltage (μV) 251.1 ± 75.8 219.4 ± 88.5 1.00 0.99–1.01 .06 Sleep architecture 20 (55.6%) 66 (55.5%) 1.00 0.47–2.13 .99 Dominant rhythm frequency (Hz) 2.3 ± 0.9 2.4 ± 1.7 NA NA .56 Variability 24 (66.7%) 69 (58.0%) 1.45 0.66–3.17 .35 Reactivity 20 (58.8%) 45 (40.5%) 2.10 0.96–4.58 .06 General slowing 35 (97.2%) 105 (90.5%) 3.67 0.46–29.4 .22 Paradoxic reactivity 10 (50%) 17 (37.0%) 1.70 0.59–4.93 .32 Asymmetry 7 (19.4%) 34 (28.8%) 0.60 0.24–1.49 .27 Outcomes Overall coma duration (hrs) 47.5 ± 25.3 74.8 ± 43.9 0.98 0.97–0.99 <.001 Full recovery 55 (90.2%) 148 (71.2%) 3.70 1.50–9.10 .004 Survival with sequelae 5 (8.2%) 27 (13.0%) 0.60 0.22–1.63 .32 Death 1 (1.6%) 33 (15.9%) 0.09 0.01–0.67 .02
Note:—HRP-II indicates histidine-rich protein, a marker of parasite burden; IWMDR+, subjects with purely subcortical white matter abnormalities, excluding those with cortical DWI abnormalities and those with basal ganglia DWI abnormalities; IWMDR−, those who did not meet criteria for IWMDR+; NA, not applicable.
↵a Values are No. (%) or means.